Indian equity benchmarks closed the week ending 18 July with modest gains, as strong first-quarter corporate earnings and a major Cabinet-approved manufacturing outlay offset investor anxiety over escalating Middle East geopolitical tensions and surging crude oil prices. The Nifty50 advanced 127.4 points, or 0.5%, while the BSE Sensex gained 582.06 points, or 0.8%, reversing the losses recorded in the prior week.

Geopolitical Pressure and the Crude Surge

Investor caution was elevated after the US Central Command (CENTCOM) confirmed a fresh wave of offensive strikes against Iran on 12 July, targeting multiple sites to degrade Tehran's capacity to threaten international shipping through the Strait of Hormuz. The escalation triggered a sharp rally in energy markets, with Brent crude surging 15.91% during the week to settle at $88.10 per barrel. Elevated oil prices are a particular concern for India, which imports roughly 85% of its crude requirements, as they widen the current account deficit and stoke inflationary pressure.

What Supported the Market

Despite the global headwinds, domestic sentiment found support from two key pillars. First, the Union Cabinet approved two significant manufacturing initiatives with a combined outlay of nearly ₹1.9 lakh crore, signalling continued policy momentum. Second, the onset of the June quarter (Q1 FY27) earnings season delivered broadly positive results from several blue-chip names.

Technology stocks were particularly in focus. TCS shares rallied following its quarterly earnings release. Tech Mahindra gained after reporting an 8.2% sequential rise in consolidated net profit to ₹1,465 crore for the quarter ended 30 June. HCL Technologies impressed investors with a 20.32% year-on-year increase in consolidated net profit to ₹4,624 crore in Q1 FY27. Reliance Industries and Jio Financial Services also announced their June quarter results during the week.

Laggards: Dr. Reddy's Under Pressure

Dr. Reddy's Laboratories remained a notable underperformer for a second straight week, after the company disclosed that commercial supplies of its semaglutide product would face delays owing to an active pharmaceutical ingredient (API)-related quality issue. The setback kept the pharma major under sustained selling pressure even as the broader market recovered.

Volatility Rises as Risks Accumulate

Market volatility climbed during the week, with India VIX rising 7.3% as participants weighed the compounding impact of geopolitical risk, elevated oil prices, and an uncertain global interest rate trajectory. This comes amid a broader pattern of risk-off episodes linked to Middle East developments, which have periodically rattled emerging-market flows in recent months.

With crude prices elevated and global uncertainty persisting, markets are likely to remain sensitive to any fresh geopolitical developments and the trajectory of the ongoing earnings season in the week ahead.